Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 7402784, 9 pages
http://dx.doi.org/10.1155/2016/7402784
Research Article

Galectin-3 Reflects Mitral Annular Plane Systolic Excursion Being Assessed by Cardiovascular Magnetic Resonance Imaging

1First Department of Medicine, University Medical Center Mannheim (UMM), Faculty of Medicine Mannheim, Heidelberg University, Mannheim, Germany
2Institute of Clinical Radiology and Nuclear Medicine, University Medical Center Mannheim (UMM), Faculty of Medicine Mannheim, Heidelberg University, Mannheim, Germany
3Institute of Clinical Chemistry, Laboratory Medicine and Transfusion Medicine, General Hospital Nuremberg, Paracelsus Medical University, Nuremberg, Germany

Received 3 July 2016; Accepted 2 November 2016

Academic Editor: Giuseppe Murdaca

Copyright © 2016 Seung-Hyun Kim et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. von Knobelsdorff-Brenkenhoff and J. Schulz-Menger, “Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology,” Journal of Cardiovascular Magnetic Resonance, vol. 18, article 6, 2016. View at Publisher · View at Google Scholar
  2. C. Doesch and T. Papavassiliu, “Diagnosis and management of ischemic cardiomyopathy: role of cardiovascular magnetic resonance imaging,” World Journal of Cardiology, vol. 6, no. 11, pp. 1166–1174, 2014. View at Publisher · View at Google Scholar
  3. S. Jha, A. Goldberg, and M. Stellingworth, “MR imaging of nonischemic cardiomyopathy,” PET Clinics, vol. 6, no. 4, pp. 475–487, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. B. Heydari and R. Y. Kwong, “Cardiac magnetic resonance imaging for ischemic heart disease: update on diagnosis and prognosis,” Topics in Magnetic Resonance Imaging, vol. 23, no. 1, pp. 21–31, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Doesch, A. Sperb, S. Sudarski et al., “Mitral annular plane systolic excursion is an easy tool for fibrosis detection by late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy,” Archives of Cardiovascular Diseases, vol. 108, no. 6-7, pp. 356–366, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. J. Matos, I. Kronzon, G. Panagopoulos, and G. Perk, “Mitral annular plane systolic excursion as a surrogate for left ventricular ejection fraction,” Journal of the American Society of Echocardiography, vol. 25, no. 9, pp. 969–974, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Hu, D. Liu, S. Herrmann et al., “Clinical implication of mitral annular plane systolic excursion for patients with cardiovascular disease,” European Heart Journal Cardiovascular Imaging, vol. 14, no. 3, pp. 205–212, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Braunwald, “Biomarkers in heart failure,” The New England Journal of Medicine, vol. 358, no. 20, pp. 2148–2159, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. R. R. van Kimmenade, J. L. Januzzi Jr., P. T. Ellinor et al., “Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure,” Journal of the American College of Cardiology, vol. 48, no. 6, pp. 1217–1224, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. M. F. Elnoamany and A. K. Abdelhameed, “Mitral annular motion as a surrogate for left ventricular function: correlation with brain natriuretic peptide levels,” European Journal of Echocardiography, vol. 7, no. 3, pp. 187–198, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. G. M. Felker, M. Fiuzat, L. K. Shaw et al., “Galectin-3 in ambulatory patients with heart failure results from the HF-ACTION study,” Circulation: Heart Failure, vol. 5, no. 1, pp. 72–78, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. U. C. Sharma, S. Pokharel, T. J. Van Brakel et al., “Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction,” Circulation, vol. 110, no. 19, pp. 3121–3128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. V. Polat, E. Bozcali, T. Uygun, S. Opan, and O. Karakaya, “Diagnostic significance of serum galectin-3 levels in heart failure with preserved ejection fraction,” Acta Cardiologica, vol. 71, no. 2, pp. 191–197, 2016. View at Google Scholar
  14. F. Edelmann, V. Holzendorf, R. Wachter et al., “Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial,” European Journal of Heart Failure, vol. 17, no. 2, pp. 214–223, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. Q.-S. Yin, B. Shi, L. Dong, and L. Bi, “Comparative study of galectin-3 and B-type natriuretic peptide as biomarkers for the diagnosis of heart failure,” Journal of Geriatric Cardiology, vol. 11, no. 1, pp. 79–82, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. E. G. Singsaas, C. A. Manhenke, K. Dickstein, and S. Orn, “Circulating galectin-3 levels are increased in patients with ischemic heart disease, but are not influenced by acute myocardial infarction,” Cardiology, vol. 134, no. 4, pp. 398–405, 2016. View at Publisher · View at Google Scholar
  17. R. A. de Boer, D. J. A. Lok, T. Jaarsma et al., “Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction,” Annals of Medicine, vol. 43, no. 1, pp. 60–68, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. F. J. Carrasco-Sánchez, O. Aramburu-Bodas, P. Salamanca-Bautista et al., “Predictive value of serum galectin-3 levels in patients with acute heart failure with preserved ejection fraction,” International Journal of Cardiology, vol. 169, no. 3, pp. 177–182, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. W. C. Meijers, J. L. Januzzi, C. Defilippi et al., “Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials,” American Heart Journal, vol. 167, no. 6, pp. 853–860.e4, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. Galectin-3, Architect System, © 2012, 2013 Abbott Laboratories.
  21. proBNP II STAT, cobas, © 2014, Roche Diagnostics.
  22. J. A. Hanley and B. J. McNeil, “A method of comparing the areas under receiver operating characteristic curves derived from the same cases,” Radiology, vol. 148, no. 3, pp. 839–843, 1983. View at Publisher · View at Google Scholar · View at Scopus
  23. N. Hrynchyshyn, P. Jourdain, M. Desnos, B. Diebold, and F. Funck, “Galectin-3: a new biomarker for the diagnosis, analysis and prognosis of acute and chronic heart failure,” Archives of Cardiovascular Diseases, vol. 106, no. 10, pp. 541–546, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. S. L. Friedman, “Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury,” Journal of Biological Chemistry, vol. 275, no. 4, pp. 2247–2250, 2000. View at Publisher · View at Google Scholar · View at Scopus
  25. M. J. Van Amerongen, M. C. Harmsen, N. Van Rooijen, A. H. Petersen, and M. J. A. Van Luyn, “Macrophage depletion impairs wound healing and increases left ventricular remodeling after myocardial injury in mice,” American Journal of Pathology, vol. 170, no. 3, pp. 818–829, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. N. G. Frangogiannis, C. W. Smith, and M. L. Entman, “The inflammatory response in myocardial infarction,” Cardiovascular Research, vol. 53, no. 1, pp. 31–47, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. H.-J. Gabius, “Cell surface glycans: the why and how of their functionality as biochemical signals in lectin-mediated information transfer,” Critical Reviews in Immunology, vol. 26, no. 1, pp. 43–79, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. N. C. Henderson, A. C. Mackinnon, S. L. Farnworth et al., “Galectin-3 regulates myofibroblast activation and hepatic fibrosis,” Proceedings of the National Academy of Sciences, vol. 103, no. 13, pp. 5060–5065, 2006. View at Publisher · View at Google Scholar
  29. N. Ahmad, H.-J. Gabius, S. André et al., “Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes,” The Journal of Biological Chemistry, vol. 279, no. 12, pp. 10841–10847, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. R. A. de Boer, A. A. Voors, P. Muntendam, W. H. Van Gilst, and D. J. Van Veldhuisen, “Galectin-3: a novel mediator of heart failure development and progression,” European Journal of Heart Failure, vol. 11, no. 9, pp. 811–817, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. Y.-H. Liu, M. D'Ambrosio, T.-D. Liao et al., “N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 296, no. 2, pp. H404–H412, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Yu, W. P. T. Ruifrok, M. Meissner et al., “Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis,” Circulation: Heart Failure, vol. 6, no. 1, pp. 107–117, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Emilsson and B. Wandt, “The relation between mitral annulus motion and ejection fraction changes with age and heart size,” Clinical Physiology, vol. 20, no. 1, pp. 38–43, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. F. W. G. Wenzelburger, Y. T. Tan, F. J. Choudhary, E. S. P. Lee, F. Leyva, and J. E. Sanderson, “Mitral annular plane systolic excursion on exercise: a simple diagnostic tool for heart failure with preserved ejection fraction,” European Journal of Heart Failure, vol. 13, no. 9, pp. 953–960, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Adel, A. M. Roushdy, and M. Nabil, “Mitral annular plane systolic excursion-derived ejection fraction: a simple and valid tool in adult males with left ventricular systolic dysfunction,” Echocardiography, vol. 33, no. 2, pp. 179–184, 2016. View at Publisher · View at Google Scholar
  36. J. X. Qin, T. Shiota, H. Tsujino et al., “Mitral annular motion as a surrogate for left ventricular ejection fraction: real-time three-dimensional echocardiography and magnetic resonance imaging studies,” European Journal of Echocardiography, vol. 5, no. 6, pp. 407–415, 2004. View at Publisher · View at Google Scholar · View at Scopus
  37. W. Tsang, H. Ahmad, A. R. Patel et al., “Rapid estimation of left ventricular function using echocardiographic speckle-tracking of mitral annular displacement,” Journal of the American Society of Echocardiography, vol. 23, no. 5, pp. 511–515, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. B. G. Sveälv, E. L. Olofsson, and B. Andersson, “Ventricular long-axis function is of major importance for long-term survival in patients with heart failure,” Heart, vol. 94, no. 3, pp. 284–289, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Ponikowski, A. A. Voors, S. D. Anker et al., “2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC,” European Heart Journal, vol. 37, no. 27, pp. 2129–2200, 2016. View at Publisher · View at Google Scholar